Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Utility and Clinical Value of Circulating Tumor Cells in Gastrointestinal Cancer

소화기계 암에서의 순환종양세포 분석과 임상적 가치

  • Hyeongjung Woo (Department of New Biology, DGIST) ;
  • Hyun Young Shin (CTCELLS Inc.) ;
  • Minseok S. Kim (Department of New Biology, DGIST)
  • 우형중 (뉴바이올로지학과, DGIST) ;
  • 신현영 ((주)씨티셀즈) ;
  • 김민석 (뉴바이올로지학과, DGIST)
  • Received : 2024.07.30
  • Accepted : 2024.08.18
  • Published : 2024.08.20
Download PDF
⟨ Previous Next ⟩

Abstract

Circulating tumor cells (CTCs) are a valuable biomarker for the diagnosis, prognosis, and therapeutic management of gastrointestinal (GI) cancers. A major challenge in GI cancer treatment is the high rate of metastasis, which significantly contributes to cancer-related mortality. CTCs are crucial in the metastatic cascade, serving as indicators of tumor progression. Therefore, the detection and molecular characterization of CTCs have prognostic potential for identifying early-stage GI cancers and assessing metastatic probability, enabling timely treatment. Moreover, CTC analysis offers a minimally invasive method for real-time monitoring of tumors. Clinicians can adjust therapeutic strategies accordingly by tracking changes in CTC count and molecular profile. Despite this promising application, no standardized protocol for CTC isolation in GI tract cancers has been established, which poses a barrier to routine clinical use. This review explores the current CTC detection methodologies, their clinical relevance in GI cancer management, and the potential integration of CTC analysis into personalized medicine. We also discuss the challenges and future directions in CTC research, focusing on clinical validation and the development of standardized procedures to fully realize the utility of CTC count for improving patient care.

Keywords

Acknowledgement

This study was supported by National Research Foundation funded by the Ministry of Science, ICT (NRF-2022R1A2C2091870).

References

  1. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335-349.e15. https://doi.org/10.1053/j.gastro.2020.02.068
  2. Li W, Ng JM, Wong CC, Ng EKW, Yu J. Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene 2018;37:4903-4920. https://doi.org/10.1038/s41388-018-0341-x
  3. Menyailo ME, Tretyakova MS, Denisov EV. Heterogeneity of circulating tumor cells in breast cancer: identifying metastatic seeds. Int J Mol Sci 2020;21:1696. https://doi.org/10.3390/ijms21051696
  4. Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther 2021;6:404. https://doi.org/10.1038/s41392-021-00817-8
  5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 1869;14:146-147.
  6. Woo HJ, Kim SH, Kang HJ, et al. Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. Theranostics 2022;12:3676-3689. https://doi.org/10.7150/thno.72511
  7. American Cancer Society. Cancer facts & figures 2024. 2024. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures. html (accessed July 30, 2024)
  8. Kauppila JH, Mattsson F, Brusselaers N, Lagergren J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open 2018;8:e021495. https://doi.org/10.1136/bmjopen-2018-021495
  9. Tustumi F, Kimura CM, Takeda FR, et al. Prognostic factors and survival analysis in esophageal carcinoma. Arq Bras Cir Dig 2016;29:138-141. https://doi.org/10.1590/0102-6720201600030003
  10. Yin XD, Yuan X, Xue JJ, Wang R, Zhang ZR, Tong JD. Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. Dis Esophagus 2012;25:750-756. https://doi.org/10.1111/j.1442-2050.2012.01326.x
  11. Matsushita D, Uenosono Y, Arigami T, et al. Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2015;22:3674-3680. https://doi.org/10.1245/s10434-015-4392-8
  12. Yu E, Allan AL, Sanatani M, et al. Circulating tumor cells detected in follow-up predict survival outcomes in trimodality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial. BMC Cancer 2022;22:746. https://doi.org/10.1186/s12885-022-09846-0
  13. Ko JMY, Lam KO, Kwong DLW, et al. Circulating tumor cell enumeration for serial monitoring of treatment outcomes for locally advanced esophageal squamous cell carcinoma. Cancers (Basel) 2023;15:832. https://doi.org/10.3390/cancers15030832
  14. Kubisch I, De Albuquerque A, Schuppan D, Kaul S, Schaich M, Stolzel U. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology 2015;89:294-303. https://doi.org/10.1159/000437373
  15. Li Y, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology 2011;58:2166-2170. https://doi.org/10.5754/hge11753
  16. Kang HM, Kim GH, Jeon HK, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer. PLoS One 2017;12:e0180251. https://doi.org/10.1371/journal.pone.0180251
  17. Lee SJ, Lee J, Kim ST, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers 2015;30:e382-e386. https://doi.org/10.5301/jbm.5000151
  18. Zou K, Yang S, Zheng L, Wang S, Xiong B. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer: a meta-analysis. Biomed Res Int 2016;2016:2765464. https://doi.org/10.1155/2016/2765464
  19. Mishima Y, Matsusaka S, Chin K, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol 2017;12:341-351. https://doi.org/10.1007/s11523-017-0493-6
  20. Li Y, Zhang X, Liu D, et al. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res 2018;24:5261-5271. https://doi.org/10.1158/1078-0432.Ccr-18-1205
  21. Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology 2018;7:e1438111. https://doi.org/10.1080/2162402x.2018.1438111
  22. Pusceddu S, Ghidini M, Torchio M, et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel) 2019;11:484. https://doi.org/10.3390/cancers11040484
  23. Gao Y, Zhu Y, Zhang Z, Zhang C, Huang X, Yuan Z. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res 2016;35:66. https://doi.org/10.1186/s13046-016-0340-0
  24. Hugenschmidt H, Labori KJ, Borgen E, et al. Preoperative CTC-detection by CellSearch®  is associated with early distant metastasis and impaired survival in resected pancreatic cancer. Cancers (Basel) 2021;13:485. https://doi.org/10.3390/cancers13030485
  25. Okubo K, Uenosono Y, Arigami T, et al. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Eur J Surg Oncol 2017;43:1050-1055. https://doi.org/10.1016/j.ejso.2017.01.241
  26. Earl J, Garcia-Nieto S, Martinez-Avila JC, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 2015;15:797. https://doi.org/10.1186/s12885-015-1779-7
  27. Buscail E, Alix-Panabieres C, Quincy P, et al. High clinical value of liquid biopsy to detect circulating tumor cells and tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front surgery. Cancers (Basel) 2019;11:1656. https://doi.org/10.3390/cancers11111656
  28. Wang Y, Yu X, Hartmann D, Zhou J. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis. HPB (Oxford) 2020;22:660-669. https://doi.org/10.1016/j.hpb.2019.11.003
  29. Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study. Ann Surg 2018;268:408-420. https://doi.org/10.1097/sla.0000000000002925
  30. Wei T, Zhang X, Zhang Q, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Lett 2019;452:237-243. https://doi.org/10.1016/j.canlet.2019.03.009
  31. Ankeny JS, Court CM, Hou S, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer 2016;114:1367-1375. https://doi. org/10.1038/bjc.2016.121
  32. Fitzmaurice C, Allen C, Barber RM, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-548. https://doi.org/10.1001/jamaoncol.2016.5688
  33. Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. JAMA Oncol 2024;10:54-62. https://doi. org/10.1001/jamaoncol.2023.5098
  34. Wang D, Yang Y, Jin L, et al. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer. J Cancer 2019;10:4552-4563. https://doi.org/10.7150/jca.30512
  35. Sastre J, Maestro ML, Gomez-Espana A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012;17:947-955. https://doi.org/10.1634/theoncologist.2012-0048
  36. Krebs MG, Renehan AG, Backen A, et al. Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer. Clin Colorectal Cancer 2015;14:115-122.e1-2. https://doi.org/10.1016/j.clcc.2014.12.006
  37. Zhao JX, Liu LR, Yang XY, Liu F, Zhang ZG. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. Oncotarget 2017;8:67918-67932. https://doi.org/10.18632/oncotarget.18912
  38. Yu H, Ma L, Zhu Y, Li W, Ding L, Gao H. Significant diagnostic value of circulating tumour cells in colorectal cancer. Oncol Lett 2020;20:317-325. https://doi.org/10.3892/ol.2020.11537
  39. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53. https://doi.org/10.2147/jhc.S61146
  40. Seo SI, Kim HS, Kim WJ, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2015;21:3928-3935. https://doi.org/10.3748/wjg.v21.i13.3928
  41. Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res 2018;78:4731-4744. https://doi.org/10.1158/0008-5472.Can-17-2459
  42. Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013;57:1458-1468. https://doi.org/10.1002/hep.26151
  43. Chen J, Cao SW, Cai Z, Zheng L, Wang Q. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients. Cancer Biomark 2017;20:487-498. https://doi.org/10.3233/cbm-170315
  44. Yin LC, Luo ZC, Gao YX, Li Y, Peng Q, Gao Y. Twist expression in circulating hepatocellular carcinoma cells predicts metastasis and prognoses. Biomed Res Int 2018;2018:3789613. https://doi.org/10.1155/2018/3789613
  45. Zhou Y, Wang B, Wu J, et al. Association of preoperative EpCAM circulating tumor cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016;16:506. https://doi.org/10.1186/s12885-016-2526-4
  46. Su K, Guo L, He K, et al. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. Front Oncol 2022;12:873830. https://doi.org/10.3389/fonc.2022.873830
  47. Ge Z, Helmijr JCA, Jansen M, et al. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Transl Oncol 2021;14:101073. https://doi.org/10.1016/j.tranon.2021.101073